Prostate Cancer Clinical Trial

Patient-Centered Communication of Life Expectancy Estimates in Genitourinary Malignancies

Summary

Investigators will conduct a randomized trial to determine if providing patient-specific life expectancy estimates during treatment counseling via a targeted, patient-centered communication approach improves shared decision making and reduces rates of overtreatment of genitourinary malignancies.

View Full Description

Full Description

Subjects in the intervention arm will be provided with life expectancy estimates specific to their age and health status. Life expectancy estimates for prostate and kidney cancer patients will be estimated by age and Charlson comorbidity score cutoffs, and life expectancy for bladder cancer patients will be determined using definitions as noted by Cho et al. Talking points will be provided to counseling physicians on how to meaningfully communicate life expectancy data. Subjects will also complete a computer-based conjoint analysis exercise prior to the counseling visit; results will be used to help physicians understand how the subject values life expectancy compared with other decision attributes. The control arm will consist of the current standard of care for treatment counseling.

The intervention will be randomized at the level of the patient after stratification by type of cancer.

All participants will be asked to fill out a validated questionnaire to measure decisional conflict at the conclusion of their counseling visit. Investigators will audiotape treatment counseling visits to allow for qualitative analysis of the quality of communication of life expectancy information. Treatment choice will be documented to assess rates of aggressive versus non-aggressive treatment among patients with limited life expectancy.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Newly diagnosed clinical T1-2 prostate adenocarcinoma with Gleason scores of 7 or less
Newly diagnosed clinical T1a kidney cancer or renal masses < 4cm
Newly diagnosed clinical T2 nonmetastatic urothelial carcinoma of the bladder

Exclusion Criteria:

Under 18 years of age
Subjects with difficulty communicating or dementia
Non-English speakers

Study is for people with:

Prostate Cancer

Estimated Enrollment:

136

Study ID:

NCT03522155

Recruitment Status:

Recruiting

Sponsor:

Cedars-Sinai Medical Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Cedars-Sinai Medical Center
Los Angeles California, 90048, United States More Info
Timothy Daskivich, MD, MSPHM
Contact
310-423-4700
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Estimated Enrollment:

136

Study ID:

NCT03522155

Recruitment Status:

Recruiting

Sponsor:


Cedars-Sinai Medical Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider